Prediction of response to dupilumab treatment
- PMID: 37167296
- DOI: 10.1093/bjd/ljad067
Prediction of response to dupilumab treatment
Conflict of interest statement
Conflicts of interest D.J.H. is or has been a consultant and/or investigator for AbbVie, Almirall, AstraZeneca, Galderma, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi and UCB. J.O. declares she has no conflicts of interest.
Comment on
-
Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab.Br J Dermatol. 2023 Apr 20;188(5):649-660. doi: 10.1093/bjd/ljad032. Br J Dermatol. 2023. PMID: 36756674
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
